

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Human Health Holdings Limited**

**盈健醫療集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1419)**

**ANNOUNCEMENT ON ESTIMATED PROFIT DECREASE  
FOR THE YEAR ENDED 30 JUNE 2017**

This announcement is made by Human Health Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”), pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the currently available information and the preliminary review of the Group’s unaudited management accounts for the year ended 30 June 2017, the profit attributable to Shareholders for the year ended 30 June 2017 is expected to decrease by approximately 45% as compared with that for the year ended 30 June 2016.

Based on the currently available information, the decrease in the profit attributable to Shareholders for the year ended 30 June 2017 was primarily due to (i) the decrease in revenue for the year ended 30 June 2017 by approximately 4% which was mainly due to the shorter period and reduced impact of the seasonal flu as compared with that for the 2015/16 winter resulting in the decrease in number of patient visits in respect of the Group’s general practice services; (ii) the increase in payroll costs due to the increase in number of staff particularly managerial staff to support the Group’s business development in Hong Kong and the People’s Republic of China (the “**PRC**”); and (iii) the increase in other operating costs such as rental cost for the Group’s business expansion in Hong Kong and the PRC where the newly opened medical centres and offices and newly developed services are at the start-up period.

The information contained in this announcement is based on a preliminary assessment from the

information currently available and is not based on any financial data or information that has been audited or reviewed by the auditor or the audit committee of the Company. Shareholders and potential investors are advised to read carefully the annual results announcement of the Company for the year ended 30 June 2017, which is expected to be released by the end of September 2017 and may differ from the information disclosed in this announcement.

**Shareholders and potential investors should exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Human Health Holdings Limited**  
**Chan Kin Ping**  
*Chairman*

Hong Kong, 1 September 2017

*As at the date of this announcement, the Board comprises Mr. Chan Kin Ping (also as Chief Executive Officer), Dr. Pang Lai Sheung, Ms. Sat Chui Wan and Mr. Poon Chun Pong as executive Directors and Dr. Lui Sun Wing, Mr. Chan Yue Kwong Michael and Mr. Sin Kar Tim as independent non-executive Directors.*